** Shares of Lucid Diagnostics LUCD.O down 24.2% to $1.25 before the bell after overnight follow-on priced
** New York-based commercial-stage co late Weds sold 12.5 mln shares at $1.20 for $15 mln gross proceeds
** Offering priced at 27.3% discount to last sale
** The subsidiary of PAVmed Inc PAVM.O plans to use net proceeds for working capital, general purposes
** LUCD had ~90.75 mln shares outstanding as of Mar 20, per most recent 10-k filing, giving it $150 mln market cap
** Co's flagship product, the EsoGuard Esophageal DNA Test, is used to screen for esophageal precancer and cancer in at-risk gastroesophageal reflux disease (GERD) patients
** Stock ended 2024 at 82 cents
** Canaccord Genuity sole bookrunner for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。